| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424165100 | Staphylococcus or Streptococcus (e.g., pneumococcus or Streptococcus pneumoniae, Streptococcus mutans, etc.) | 33 |
| 20080311129 | ADHERENCE INHIBITOR DIRECTED TO AND METHOD OF MAKING AND USING - A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease the colonization of the oropharnyx, and therefore decrease symptoms of the sore inflamed throat and ultimately decrease the need for antibiotics. | 12-18-2008 |
| 20090041782 | Novel serotype streptococcus mutans and utilization of the same - A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of | 02-12-2009 |
| 20090081236 | IMMUNIZING COMPOSITIONS AND METHODS OF USE - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 03-26-2009 |
| 20090162379 | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor - Provided herein is a method for identifying small molecule inhibitors of | 06-25-2009 |
| 20100092487 | TOXIC DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in | 04-15-2010 |
| 20100150943 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA - The invention relates to the identification of a new adhesin islands within the genomes of several Gram positive | 06-17-2010 |
| 20100166772 | ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n - The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against | 07-01-2010 |
| 20100233185 | Caries Risk Test for Predicting and Assessing the Risk of Disease - Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level. | 09-16-2010 |
| 20110033479 | PROTEINS EZRIN, SERPIN B5, PEROXIREDOXIN-2 AND HEAT SHOCK PROTEIN BETA-1 AS AUTOANTIGENS FOR PSORIASIS VULGARIS AND POSTSTREPTOCOCCAL DISEASES - The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein β1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions. | 02-10-2011 |
| 20110038879 | IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - Compositions for preventing and/or treating | 02-17-2011 |
| 20110064745 | Therapeutic Antibodies, Antibody Fragments And Antibody Conjugates - The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A | 03-17-2011 |
| 20110091480 | Antigen-Binding Proteins Targeting S. Aureus Orf0657n - The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an | 04-21-2011 |
| 20110171237 | PHEP, AN AMINO ACID PERMEASE OF STAPHYLOCOCCUS AUREUS - The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. | 07-14-2011 |
| 20110217312 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 09-08-2011 |
| 20120087930 | Marker of Streptococcus Anginosus/ Streptococcus Constellatus (MOAC) and Uses Thereof - The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting | 04-12-2012 |
| 20120107327 | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from | 05-03-2012 |
| 20120148601 | BACTERIAL SUPERANTIGEN VACCINES - The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described. | 06-14-2012 |
| 20120171223 | HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B - This invention provides antibodies that specifically bind and neutralize | 07-05-2012 |
| 20120201833 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-09-2012 |
| 20120201834 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-09-2012 |
| 20120301481 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 11-29-2012 |
| 20130052204 | (POLY)-GLYCEROLPHOSPHATE-BASED ANTI-GRAM POSITIVE BACTERIAL VACCINE - Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen. | 02-28-2013 |
| 20130095115 | STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF - Disclosed herein are isolated and purified | 04-18-2013 |
| 20130164308 | STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODIES AND USES THEREOF - The present invention provides antagonizing antibodies that bind to | 06-27-2013 |
| 20140017258 | Compositions against bacterial toxins - Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents. | 01-16-2014 |
| 20140037650 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEINS ISDA OR ISDB - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 02-06-2014 |
| 20140037651 | DEPLETED ANTI-STAPHYLOCOCCAL ENTEROTOXINS POLYCLONAL ANTIBODIES, PREPARATION AND USES THEREOF - The present invention relates to the preparation of a set of depleted polyclonal antibodies, each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and its use for multiplex detection. | 02-06-2014 |
| 20140072577 | ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE - Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments. | 03-13-2014 |
| 20140234338 | THERAPEUTIC AGENT FOR USE IN A METHOD OF TREATING PSORIASIS OR ATOPIC DERMATITIS - The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti- | 08-21-2014 |
| 20140234339 | PEPTIDE OR ARRANGEMENT OF PEPTIDES FORMING A STAPHYLOCOCCUS AUREUS EPITOPE BINDING SITE - The invention concerns a peptide or arrangement of peptides forming a | 08-21-2014 |
| 20160024190 | ANTI-STAPHYLOCOCCUS ANTIBODY, METHOD FOR MANUFACTURING SAME, AND USAGE OF SAME - [Problem] The present invention addresses the problem of providing an anti- | 01-28-2016 |
| 20160120852 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS - Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria. | 05-05-2016 |
| 20190142922 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | 05-16-2019 |
